SCH-23390 maleate (R-(+)-SCH-23390 maleate) is a potent and selective dopamine D1-like receptor antagonist, specifically targeting D1 and D5 receptors with Ki values of 0.2 nM and 0.3 nM, respectively.

D5:0.3 nM (Ki), GIRK:268 nM, D1:0.2 nM (Ki), 5-HT2C:9.3 nM (Ki)

SCH-23390 (1 μM) reverses the Isosibiricin-mediated inhibition of the NLRP3/caspase-1 inflammasome pathway, including the suppression of NLRP3 expression and the cleavages of caspase-1 and IL-1β in LPS-induced BV-2 cells[4].

SCH-23390 can eliminate systemic seizures caused by chemical convulsions:pilocarpine and soman. SCH-23390 has also been used in studies of other neurological disorders in which the dopamine system has been implicated(psychosis and Parkinson's disease). Apart from the study of neurological disorders, SCH-23390 has been wildly used as a tool in the topographical determination of brain D1 receptors in rodents, nonhuman primates, and humans[1]. SCH-23390 is a very short-acting compound with an elimination half-life of around 25 min following administration of 0.3 mg/kg i.p. in the rat[1]. SCH-23390 augments dopamine-induced ductus constriction in CD-1 mouse vessels under newborn O2 conditions[5].